Jaffer Naqvi1, Anna Lee2,3, Ariel Lederman1,4, Ami Kavi1,4, Virginia W Osborn5, David Schreiber1,6. 1. Department of Radiation Oncology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Mail Stop #1211, Brooklyn, NY, 11203, USA. 2. Department of Radiation Oncology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Mail Stop #1211, Brooklyn, NY, 11203, USA. anna.lee@downstate.edu. 3. Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, NY, USA. anna.lee@downstate.edu. 4. Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, NY, USA. 5. Department of Radiation Oncology, Elmhurst Hospital Center, Queens, NY, USA. 6. Summit Medical Group, Berkeley Heights, NJ, USA.
Abstract
PURPOSE: Anal mucosal melanoma is an uncommon malignancy of the anal canal, with few large studies available to establish clear trends in the treatment modalities presently available. The primary goal of this study was to identify the patterns of care in the treatment of anal melanoma and secondarily to determine outcomes. METHODS: This was a retrospective study performed utilizing the National Cancer Database (NCDB). A total of 787 patients diagnosed with anal melanoma between 2004 and 2014 were selected, of which 398 had staging information. The four treatment groups analyzed were surgical excision alone, surgical excision and radiation therapy, surgical excision and immunotherapy/chemotherapy, and radiation therapy plus minus immunotherapy/chemotherapy. Treatment was grouped by extent of disease; the Kaplan-Meier method was used to analyze overall survival and multivariate Cox proportional model was used to identify factors associated with overall survival. RESULTS: The majority of patients presented with either node-positive (39.4%) or metastatic disease (37.4%). Patients with surgical excision and radiation therapy had the highest median survival at 32.3 months. This is in contrast with those receiving surgical excision alone (22.9 months), surgery and immunotherapy/chemotherapy (18.4 months), and radiation without surgery (5.1 months) (p < 0.0001). CONCLUSIONS: Treatment with surgical excision was the most common initial treatment with no single modality superior over another in this rare entity.
PURPOSE: Anal mucosal melanoma is an uncommon malignancy of the anal canal, with few large studies available to establish clear trends in the treatment modalities presently available. The primary goal of this study was to identify the patterns of care in the treatment of anal melanoma and secondarily to determine outcomes. METHODS: This was a retrospective study performed utilizing the National Cancer Database (NCDB). A total of 787 patients diagnosed with anal melanoma between 2004 and 2014 were selected, of which 398 had staging information. The four treatment groups analyzed were surgical excision alone, surgical excision and radiation therapy, surgical excision and immunotherapy/chemotherapy, and radiation therapy plus minus immunotherapy/chemotherapy. Treatment was grouped by extent of disease; the Kaplan-Meier method was used to analyze overall survival and multivariate Cox proportional model was used to identify factors associated with overall survival. RESULTS: The majority of patients presented with either node-positive (39.4%) or metastatic disease (37.4%). Patients with surgical excision and radiation therapy had the highest median survival at 32.3 months. This is in contrast with those receiving surgical excision alone (22.9 months), surgery and immunotherapy/chemotherapy (18.4 months), and radiation without surgery (5.1 months) (p < 0.0001). CONCLUSIONS: Treatment with surgical excision was the most common initial treatment with no single modality superior over another in this rare entity.
Authors: Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen Journal: Cancer Date: 2005-03-01 Impact factor: 6.860
Authors: Markus V Heppt; Alexander Roesch; Benjamin Weide; Ralf Gutzmer; Friedegund Meier; Carmen Loquai; Katharina C Kähler; Anja Gesierich; Markus Meissner; Dagmar von Bubnoff; Daniela Göppner; Max Schlaak; Claudia Pföhler; Jochen Utikal; Lucie Heinzerling; Ioana Cosgarea; Jutta Engel; Renate Eckel; Alexander Martens; Laura Mirlach; Imke Satzger; Gabriele Schubert-Fritschle; Julia K Tietze; Carola Berking Journal: Eur J Cancer Date: 2017-06-07 Impact factor: 9.162
Authors: Adrienne Callahan; William F Anderson; Sital Patel; Jill S Barnholtz-Sloan; Jeremy S Bordeaux; Margaret A Tucker; Meg R Gerstenblith Journal: Dermatol Surg Date: 2016-01 Impact factor: 3.398
Authors: Danielle M Bello; Elizabeth Smyth; Daniel Perez; Shaheer Khan; Larissa K Temple; Charlotte E Ariyan; Martin R Weiser; Richard D Carvajal Journal: Dis Colon Rectum Date: 2013-02 Impact factor: 4.585
Authors: Esther Jutten; Schelto Kruijff; Anne Brecht Francken; Martijn F Lutke Holzik; Barbara L van Leeuwen; Henderik L van Westreenen; Kevin P Wevers Journal: BJS Open Date: 2021-11-09